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Abstract 39	
 40	
Survival during lung injury requires a coordinated program of damage limitation and 41	
rapid repair. CD34 is a cell surface sialomucin expressed by epithelial, vascular and 42	
stromal cells that promotes cell adhesion, coordinates inflammatory cell recruitment, and 43	
drives angiogenesis. To test whether CD34 also orchestrates pulmonary damage and 44	
repair, we induced acute lung injury in wild type (WT) and Cd34-/- mice by bleomycin 45	
(BLM) administration. We found that Cd34-/- mice displayed severe weight loss and early 46	
mortality compared to WT controls. Despite equivalent early airway inflammation to WT 47	
mice, CD34-deficient animals developed interstitial edema and endothelial delamination, 48	
suggesting impaired endothelial function. Chimeric Cd34-/- mice reconstituted with WT 49	
hematopoietic cells exhibited early mortality compared to WT mice reconstituted with 50	
Cd34-/- cells, supporting an endothelial defect. CD34-deficient mice were also more 51	
sensitive to lung damage caused by influenza infection, showing greater weight loss and 52	
more extensive pulmonary remodeling. Together our data suggest that CD34 plays an 53	
essential role in maintaining vascular integrity in the lung in response to chemical- and 54	
infection-induced, tissue damage. 55	
  56	
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Introduction 57	
Although the adult lung has a robust capacity to regenerate following injury, 58	
dysregulation of normal wound healing processes leads to fibrosis and loss of organ 59	
function. These observations have prompted extensive studies into identification of lung 60	
progenitor populations capable of facilitating lung repair (1, 2).  The cell surface 61	
sialomucin CD34 is a widely used marker for the enrichment of primitive multipotent 62	
hematopoietic cells for bone marrow (BM) transplantation (3, 4).  More recently, its 63	
utility as a marker for progenitor cells has been extended to non-hematopoietic subsets 64	
including muscle satellite cells (5), hair follicle stem cells (6), multipotent stromal cells 65	
(7, 8), bronchoalveolar stem cells (BASCs) (9, 10) and lung-resident endothelial 66	
progenitors (11).  Since CD34 is highly expressed by multiple progenitor populations and 67	
downregulated in differentiated states, it has been hypothesized that CD34 may play a 68	
role in cycling of undifferentiated precursors (12), but functional studies instead suggest 69	
that CD34 is an important regulator of cell adhesion and chemotaxis.  In lymphoid tissues, 70	
a distinct glycoform of CD34 is expressed by high endothelial venules (HEVs) and serves 71	
as a ligand for L-selectin on lymphocytes thereby mediating naïve cell recruitment to 72	
lymph nodes (13).  While this suggests that CD34 can, in some cases, facilitate adhesion, 73	
this glycoform of CD34 is exquisitely specific to rare HEVs and, thus, is unlikely to 74	
promote adhesion in other tissues.  CD34 is also expressed by a number of hematopoietic 75	
subsets including eosinophils (14, 15), mast cells (14, 16, 17), dendritic cell (DC) 76	
precursors (18), fibrocytes, and circulating endothelial progenitors (19, 20).  Intriguingly, 77	
deletion of CD34 in mast cells results in homotypic aggregation suggesting an alternate 78	
role as a blocker of adhesion (17).  We have also noted impaired chemokine-dependent 79	
migration of eosinophils arguing for a role in facilitating cell mobility and chemotaxis.  80	
Consistent with these observations, Cd34-/- mice are resistant to a variety of inflammatory 81	
diseases due to defective inflammatory cell recruitment to peripheral tissues (14, 15, 18, 82	
21).  While this suggests an important role for CD34 in inflammatory cell trafficking, its 83	
function on non-hematopoietic and structural cells during tissue remodeling remains 84	
unknown. 85	
Because CD34 is expressed by cells thought to mediate lung regeneration 86	
(epithelia, endothelia and mesenchyme) we have now investigated its function in two 87	
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models of lung injury.  Bleomycin (BLM) inhalation results in damage to pneumocytes 88	
and endothelia and is characterized by an inflammatory phase and vascular leak followed 89	
by the accumulation of extracellular matrix in the parenchyma resulting in abnormal 90	
alveolar architecture and compromised function (1, 22, 23).  Based on the well-91	
documented contribution of chronic inflammation to dysregulated tissue repair, we 92	
speculated that Cd34-/- mice would be protected from the development of fibrosis.  93	
Surprisingly, we find that Cd34-/- mice are extremely sensitive to BLM-induced damage 94	
and exhibit a higher incidence of morbidity and mortality than their WT counterparts.  95	
Ultrastructural analyses of BLM-treated Cd34-/- lungs reveal interstitial edema in the 96	
alveolar walls and delamination of endothelial cells from the basal lamina.  Similar 97	
experiments with BM chimeric mice indicate that sensitivity to BLM is due to the 98	
selective loss of CD34 on non-hematopoietic cells.  Moreover, Cd34-/- mice exhibited 99	
more pronounced evidence of epithelial remodeling in response to influenza infection.  In 100	
aggregate, these studies argue that CD34 plays a protective role in maintaining vascular 101	
integrity and basal lamina adhesion and thereby facilitates tissue repair. 102	
 103	
Materials and Methods 104	
Mice 105	
C57BL/6J (WT), Cd34-/-, B6.SJL-PtprcaPepcb/BoyJ (CD45.1), and B6.129S4-106	
Pdgfratm11(EGFP)Sor/J (PDGFRα EGFP) mice were maintained under specific pathogen-free 107	
conditions at the BRC.  Chimeric mice were generated by transplanting 107 BM cells 108	
from mice expressing CD45.2 (WT or Cd34-/-) or CD45.1 intravenously (i.v.) into 109	
lethally irradiated CD45.1 or CD45.2 recipients.  BM reconstitution efficiency was 110	
assessed by congenic CD45 expression by peripheral blood leukocytes.  All procedures 111	
were approved by the UBC Animal Care Committee. 112	
 113	
Lung injury models 114	
Mice were challenged with bleomycin (BLM) (PPC) endotracheally (e.t.) at a dose of 2.5 115	
or 5.0 U/kg, or i.v. at a dose of 1.6 U/mouse.  Static lung elastance was measured by 116	
performing volume-regulated perturbations on anesthetized and tracheotomized mice 117	
using a flexiVent apparatus (SCIREQ) (24).  Mice were challenged intranasally with 2.90 118	
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x 103 EID50 of influenza A/strain PR8 (H1N1).  Cytokines in bronchoalveolar lavage 119	
fluid (BALF) or lung homogenates were quantified using a V-plex multi-spot assay 120	
(Meso Scale Discoveries). 121	
 122	
Histology and immunohistochemistry 123	
Formalin-fixed and paraffin-embedded lungs were cut into 5-µm sections for Masson’s 124	
trichrome or hematoxylin and eosin staining.  For immunostaining, lung sections 125	
underwent antigen retrieval and were stained using antibodies against CD34 (RAM34) 126	
(eBiosciences), podocalyxin (AF1556) (R&D Systems), GFP (ab13970) (Abcam), 127	
vimentin (ab92547) (Abcam), surfactant protein C (AB3786) (Millipore), E-cadherin 128	
(36/E-cad) (BD), and keratin 5 (Poly9059) (Biolegend).  Sections were then incubated 129	
with AlexaFluor-conjugated antibodies and mounted using Prolong Gold Antifade with 130	
DAPI (Life).  Optical z-stack images were captured on a Leica SP5X confocal 131	
microscope and morphometric analysis was performed using ImageJ. 132	
 133	
Assessment of pulmonary vascular leak 134	
Vascular leak was evaluated by a modified Miles assay as described previously (25, 26).  135	
Mice were injected i.v. with 20 mg/kg Evans blue dye (EBD).  After one hour, mice were 136	
anesthetized by intraperitoneal injection of avertin, followed by perfusion with 2 mM 137	
EDTA PBS.  After excision, lungs were transferred to formamide for EBD extraction.  138	
The optical density of formamide was read at 620 nm and 740 nm on a 139	
spectrophotometer; the amount of dye per gram lung tissue was calculated using a lung 140	
specific correction factor (25, 26). 141	
 142	
Transmission electron microscopy 143	
Lungs were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer.  Tissues were 144	
processed as described previously (27) and imaged using a FEI Tecnai 12 Transmission 145	
Electron Microscope. 146	
 147	
Flow cytometry  148	
BALF was collected by three tracheal instillations and aspirations of 1 mL PBS. Tissues 149	
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were digested with collagenase D (1.5 U/mL) and dispase II (2.4 U/mL) (Roche) for 30 150	
minutes.  Samples were then incubated with anti-CD16/32 to block nonspecific antibody 151	
binding.  Fluorescence-conjugated antibodies to CD45 (I3/2), CD11c (N418), CD3e 152	
(145-2C11), CD8 (53.67), CD4 (GK1.5), B220 (RA3-6B2), Ly6B (7/4) (Abcam), 153	
SiglecF (E50-2440) (eBiosciences), CD34 (RAM34) (eBiosciences), CD31 (390) 154	
(eBiosciences), PDGFRα (APA5) (eBiosciences), Sca1 (D7) (eBiosciences), and EpCAM 155	
(G8.8) (eBiosciences) were used.  For EdU uptake experiments, mice were given 1 mg 156	
EdU daily by intraperiotenal injections; EdU detection was performed using the Click-IT 157	
assay kit (Life).  Data was acquired on a BD LSRII and analyzed with FlowJo Software.  158	
All antibodies were generated in-house (UBC AbLab) unless otherwise indicated. 159	
 160	
Statistics 161	
Survival data are presented as Kaplan-Meier curves and analyzed with a log rank test.  162	
Normality of the data was assessed using the Shapiro-Wilk test; Student’s t-test or Mann-163	
Whitney test were used to determine significance.  Statistical analyses were performed 164	
using Prism 5.0. 165	
 166	
Results 167	
Early mortality but unaltered fibrosis in Cd34-/- mice following BLM challenge 168	
To assess the role of CD34 in lung injury and fibrosis, Cd34-/- and WT mice were treated 169	
endotracheally with a single dose of BLM.  Strikingly, after administration of 5.0 U/kg or 170	
2.5 U/kg of BLM  (e.t.), Cd34-/- mice showed a significant dose-dependent increased 171	
frequency of mortality compared with WT controls (Fig 1A & 1B).  Nearly all mortality 172	
in Cd34-/- mice at the 2.5 U/kg BLM dose occurred prior to day 10.  Since the onset of 173	
fibrosis in this model is known to occur at approximately two weeks following tracheal 174	
administration of BLM (23), these data suggest that early morbidity is associated with the 175	
acute exudative phase of the disease and independent of fibrosis.  To further corroborate 176	
Cd34-/- mouse sensitivity to BLM in a systemic treatment regime, we assessed animal 177	
response following intravenous administration of 1.6 U/mouse BLM.  Again, Cd34-/- 178	
mice experienced significantly greater weight loss than WT controls with nearly all Cd34-179	
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/- animals reaching their humane endpoint by day 6 (Fig 1C).  In summary, CD34 plays a 180	
protective role in bleomycin-induced lung injury prior to the development of fibrosis. 181	
 182	
Although there was a clear increase in early mortality in Cd34-/- mice, sufficient numbers 183	
of these mice tolerated the lower dose of BLM to permit the evaluation of lung fibrosis 184	
21 days after treatment.  Quantitative analyses of Masson’s trichrome stained lung 185	
sections revealed similar degrees of fibrotic remodeling in WT and Cd34-/- animals (Fig 186	
1D & 1E). Moreover, static lung elastance was similar in BLM-treated WT and Cd34-/- 187	
animals suggesting that loss of CD34 does not alter this functional outcome of fibrosis 188	
(Fig 1F).  To eliminate the possibility of a biased assessment of fibrosis selectively in 189	
mice that survived initial lung damage, we evaluated WT and Cd34-/- mice after 190	
endotracheal treatment with a lower BLM dose (1.25 U/kg) to ensure 100% survival by 191	
day 18 post-treatment.  Again, no significant differences in fibrotic indices were observed 192	
between WT and Cd34-/- animals (Fig S1).  We conclude that loss of CD34 exacerbates 193	
the early phase of BLM-induced injury but has no effect on the later fibrotic responses. 194	
 195	
CD34 does not alter acute lung inflammation in response to BLM 196	
Because we have previously observed attenuated allergic inflammatory responses in the 197	
lungs of Cd34-/- mice (14, 18), we evaluated whether the acute inflammation that occurs 198	
after BLM-treatment was altered by loss of CD34.  Total CD45+ leukocyte numbers in 199	
the BALF were similar in both WT and Cd34-/- mice three and six days after BLM-200	
induced damage (Fig 2A).  Differential analyses revealed equivalent frequencies of 201	
macrophage, neutrophil, and lymphocyte subsets (Fig 2B).  The only significant 202	
alteration was a decrease in the frequency of infiltrating eosinophils (representing <3% of 203	
the infiltrate in WT mice and <1% in Cd34-/- mice) six days after BLM challenge (Fig 204	
2B).  This reflects a documented role of CD34 in recruitment of eosinophils to the lung 205	
(14, 28).  We also observed similar levels of pro-inflammatory cytokines IL-1β, IL-6, 206	
CXCL1, and TNFα in damaged lung tissue of Cd34-/- and WT animals 6 days after 207	
damage (Fig 2C).  In summary, because of the similar degree of inflammation, we 208	
conclude that differences in infiltrating inflammatory cells is unlikely to account for the 209	
increased mortality in BLM-treated Cd34-/- mice. 210	
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 211	
Interstital edema in BLM-treated Cd34-/- lung 212	
Morbidity within the first week of BLM treatment can also be attributed to exacerbated 213	
exudative responses during acute lung injury; such pathological features include 214	
disruption of endothelial and epithelial barriers resulting in leakage of circulatory 215	
contents into the interstitium and edema (22, 29).  We previously demonstrated increased 216	
vascular leak in lungs of Cd34-/- animals in a model of occupational asthma (18). To 217	
evaluate CD34 function in the maintenance of vascular integrity in response to acute lung 218	
injury, we assessed vascular leak in WT and Cd34-/- mice 6 days after bleomycin 219	
exposure using a modified Miles assay (25, 26).  We found that Cd34-/- lung tissues 220	
displayed enhanced vascular leak as measured by Evans blue dye extracted from the lung 221	
interstitium (Fig 3A).  Moreover, we observed a strong correlation between weight loss 222	
and severity of vascular leak (Fig 3B).   223	
 224	
In our evaluation of histological sections of H&E-stained lung tissues 6 days after 225	
bleomycin treatment, we did not observe profound differences in pathology associated 226	
with acute respiratory distress (Fig S2).  This prompted us to analyzed WT and Cd34-/- 227	
lungs at the ultrastructure level by TEM.  Evaluation of PBS-treated WT and Cd34-/- 228	
lungs did not reveal differences in the structure or localization of interstitial collagen and 229	
elastin, alterations in capillary endothelial or type 1 epithelial tight junctions, or cell-basal 230	
lamina interactions (Fig S3).  In contrast, six days after BLM challenge, we detected 231	
hypertrophy of type 1 pneumocytes in WT and Cd34-/- lung sections, which is indicative 232	
of injury (Fig 4A-F).  Strikingly, BLM-treated Cd34-/- lung specimens exhibit extensive 233	
edema within the interstitium and delamination of the endothelia as evidenced by the 234	
exposed interstitial collagen and the disruption in the epithelial and capillary endothelial 235	
basal lamina interactions.  Thus, the ultrastructure data suggests that CD34 plays a role in 236	
maintaining appropriate structural integrity of the alveolar wall in response to acute 237	
damage. 238	
 239	
CD34 is expressed by endothelia and mesenchymal subsets, but not by epithelia in 240	
normal lung 241	
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While previous work has suggested that, in the lung, CD34 is expressed primarily by 242	
endothelial and mesenchymal cells, there are conflicting reports regarding the expression 243	
of CD34 on lung epithelial progenitors (9, 30, 31).  To address this, we performed 244	
immunohistochemical analyses with antibodies against CD34 and used Cd34-/- lung 245	
samples as controls. CD34+ cells were detected in nearly all compartments except the 246	
large airway epithelia, with minimal background in knockout-control sections (Fig S4).  247	
From the analysis of confocal z stack images, CD34 is expressed by podocalyxin+ 248	
endothelia in addition to PDGFRα+ and vimentin+ fibrobroblast subsets (Fig 5A & 5B).  249	
Co-staining with antibodies against E-cadherin (E-cad) and surfactant protein C (SfpC) 250	
indicate that CD34 is not expressed by epithelia in the distal airways or the 251	
bronchoalveolar duct junctions (BADJs) where CD34-expressing epithelial progenitors 252	
were previously reported (Fig 5C) (9).  This is consistent with flow cytometric data, 253	
which show that CD34+ cells co-stain with the endothelial specific antigen CD31 and the 254	
majority of PDGFRα+ fibroadipogenic progenitors (FAPs) enriched by Sca1+ selection. 255	
Moreover, we find a lack of CD34 expression in sorted EpCAM+ epithelial cells (Fig 5D).  256	
 257	
Pulmonary fibroblasts represent a heterogeneous population; studies indicate that lung 258	
PDGFRα+ cells consist of desmin+ lipofibroblasts that support pneumocyte maintenance 259	
in alveolosphere cultures and proliferate in response to BLM treatment (32, 33).  260	
However, we saw equivalent expansion and proliferation of this fibroblast population in 261	
WT and Cd34-/- mice, analyzed six days following BLM damage (Fig 5E).  We conclude 262	
that CD34 is not expressed by lung epithelial progenitors and, although it is expressed by 263	
fibroblasts, loss of CD34 has no effect on the proliferative response of these cells or their 264	
ability to produce matrix in late stage disease. 265	
 266	
Early mortality in BLM-treated Cd34-/- mice is independent of its expression by 267	
hematopoietic cells 268	
Previously, we observed increased vascular leakage in Cd34-/- mice during autoimmune 269	
arthritis (34) and, thus, we hypothesize that this vascular cell intrinsic function of CD34 270	
could contribute to the early mortality phenotype observed in the current study.  To 271	
conclusively exclude the possibility that this enhanced mortality reflects a defective 272	
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hematopoietic function for CD34, we generated BM chimeric mice with selective loss of 273	
CD34 in either the hematopoietic or non-hematopoietic compartments (Fig 6A & 6D).  274	
Following BLM challenge by endotracheal or intravenous treatment, lethally irradiated 275	
Cd34-/- mice transplanted with WT BM exhibited a significantly higher incidence of 276	
mortality and weight loss compared with the WT recipients (Fig 6B & 6C).  Conversely, 277	
lethally irradiated WT CD45.1 animals transplanted with either Cd34-/- or WT BM and 278	
subsequently challenged with BLM displayed no significant differences in mortality rate 279	
or weight loss (Fig 6E & 6F).  These data suggest that the selective loss of CD34 from 280	
non-hematopoietic tissues contributes to increased sensitivity to BLM challenge. 281	
 282	
Loss of CD34 results in increased influenza infection-induced tissue remodeling 283	
Next, we investigated whether CD34-deficiency altered responses to H1N1 influenza 284	
infection which induces extensive damage in the bronchioles and alveolar regions (1).  285	
Following infection, Cd34-/- mice displayed significantly greater weight loss than WT 286	
animals over the disease course (Fig 7A).  Again, the overall inflammatory responses 287	
were similar in Cd34-/- and WT animals as the numbers of inflammatory infiltrates in the 288	
airways were comparable at days 7 and 12 post-infection (Fig 7B).  Moreover, 289	
differential analyses indicate that myeloid, neutrophil, eosinophil, and lymphocyte 290	
subsets were unaltered due to loss of CD34 (Fig 7C). Interestingly, however, we found 291	
greater evidence of pathology in lung sections of Cd34-/- animals; this was assessed by 292	
the quantification of tissue area displaying abnormal alveolar architecture and high 293	
cellular density accompanied by loss of airway space (Fig 7D & 7E).  Although we found 294	
that keratin 5 (Krt5) positive staining was restricted to the epithelial cells in the 295	
bronchioles of WT lung sections, Krt5-expressing clusters were more abundant, 296	
appearing in the peribronchial regions and in the distal airways of Cd34-/- lung tissues 297	
arguing for greater disease severity.  In summary, we find that loss of CD34 results in 298	
more pronounced sensitivity to influenza-induced tissue injury as evidenced by 299	
unresolved tissue remodeling. 300	
 301	
Discussion 302	
Inflammatory mediators have a clear association with the development and progression 303	
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of lung fibrosis, particularly in cases arising from exposure to environmental irritants, 304	
infection (35).  Our previous work suggested a key role for CD34 in the recruitment of 305	
inflammatory subsets and that Cd34-/- mice exhibit attenuated pathological features of 306	
lung or intestinal inflammation (14, 15, 18, 21).  However, the relevance of CD34 in 307	
responses to lung injury, remodeling, and fibrosis, has not been examined.  Given the 308	
importance of CD34 in mast cell and eosinophil trafficking, we postulated a function in 309	
fibrotic disease (12, 14, 17, 28).  The accumulation of eosinophils and mast cells in the 310	
lung has previously been associated with idiopathic pulmonary fibrosis (IPF).  Elevated 311	
eosinophils in the BALF is associated with poor prognosis (36); moreover, pathological 312	
contributions of eosinophils to IPF have been attributed to the cytotoxic factors they 313	
produce (37, 38), or the pro-fibrogenic factors that induce excessive remodeling (39-41).  314	
Although we did observe a reduced frequency of eosinophils recruited to the lung in 315	
Cd34-/- mice early after BLM treatment, this did not have a protective effect.  Thus, in the 316	
BLM model, eosinophils appear to be largely dispensable.  Although eosinophilia and 317	
Th2 cytokines have previously been reported to be promoters of BLM-induced fibrosis 318	
(39, 40, 42), our findings are consistent with more recent studies demonstrating that the 319	
fibrosis is primarily Th17 driven and independent of IL-13 signaling (43, 44).  320	
Importantly, the pro-fibrotic effects of IL-17A have been highlighted in several disease-321	
associated contexts (45, 46). 322	
 323	
Instead, loss of CD34 renders mice extremely sensitive to BLM-induced mortality with 324	
animals displaying microstructural loss of endothelial cell integrity and interstitial edema.  325	
Nearly all incidences of morbidity and mortality occur prior to the appearance of scarring 326	
in the lungs and the late phase fibrosis and tissue remodeling is equivalent in WT and 327	
Cd34-/- mice.  Because the single-dose BLM treatment model is associated with a 328	
transient and self-limiting fibrotic response we can not rule out a more subtle effect of 329	
CD34 loss in more robust models of fibrosis (23).  Nevertheless, our data suggest that 330	
CD34 is dispensable for the debilitating production of matrix in response to lung injury 331	
and that, instead, it plays a role during a transient window before the remodeling and 332	
fibrotic response.  This result was confirmed in a second, influenza-driven model of lung 333	
injury where tissue remodeling is a prominent feature.  Here too, CD34 appears to be 334	
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dispensable in the inflammatory response, but Cd34-/- mice displayed greater weight loss 335	
and their lungs displayed a more pronounced pathology, accompanied by the appearance 336	
of Krt5+ epithelial clusters in the bronchioles and in the distal airways.  While Krt5+ 337	
epithelial progenitors are necessary for regeneration to restore gas exchange, their 338	
accumulation may be indicative of increased susceptibility to damage or unresolved 339	
tissue remodeling (47, 48). 340	
 341	
Previously we have noted that loss of CD34 results in altered vascular integrity in a 342	
number of inflammatory settings including autoimmune arthritis (34), hypersensitivity 343	
pneumonitis (18), and tumour formation (49).  Because we observed no major differences 344	
in the number of BALF infiltrates or levels of pro-inflammatory cytokines in Cd34-/- and 345	
WT animals our data suggest the exacerbated interstitial edema observed in Cd34-/- 346	
animals is a cell intrinsic defect of the endothelium.  BM chimera experiments further 347	
support a non-hematopoietic origin of this phenotype as the mortality occurred in the 348	
absence of CD34 on hematopoietic cells.  Vascular integrity can be modulated by 349	
changes in junctional proteins that alter cell-cell interactions and integrin-dependent cell-350	
matrix interactions (50).  Consistent with altered integrin dependent adhesion, but normal 351	
cell junctions, TEM evaluation of BLM-challenged Cd34-/- lungs reveals extensive 352	
interstitial edema yet the endothelial-endothelial junctional complexes remain intact.  353	
Thus, our data suggest that CD34 plays a role in maintaining the integrity of endothelial 354	
adhesion to the basal lamina. 355	
 356	
In many ways, the decreased adhesion of Cd34-/- endothelia to basal lamina is counter-357	
intuitive.  Previously we have shown that CD34 and its close relative, podocalyxin, are 358	
heavily-glycosylated and negatively-charged sialomucins that provide an anti-adhesive 359	
quality to hematopoietic cells, developing endothelia and epithelial tumor cells (12, 17, 360	
51-53).  It is noteworthy, however, that we and others have found that the anti-adhesive 361	
podocalyxin and active integrin signaling cooperate to facilitate the establishment of 362	
distinct integrin-linked basolateral/matrix bound surfaces and integrin-free, podocalyxin-363	
rich, non-adhesive apical domains (12, 25, 51, 54).  Thus, loss of CD34 would weaken 364	
vessel integrity; an effect that we observe via TEM analyses of Cd34-/- endothelia after 365	
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BLM treatment.  Integrin dependent adhesion is primarily regulated by changes in 366	
conformation (affinity) and activation dependent clustering (avidity) (55).  Therefore we 367	
speculate that loss of CD34 prevents integrins from adopting an active conformation or 368	
limits the ability of integrins to effectively cluster at the basolateral domains and promote 369	
adhesion.  Intriguingly, we have found that overexpression of CD34-type proteins in 370	
epithelial cell lines tends to facilitate segregation of apical and basolateral proteins and 371	
the establishment of these domains in cells undergoing primary adhesion (52).  Moreover 372	
cells that lack these proteins exhibit a delay in the recruitment of integrins to basolateral 373	
domains.  Thus, delamination of endothelia observed in the current study may reflect an 374	
impaired ability to properly localize active integrins to the basal lamina rather than a loss 375	
of integrin expression per se.  Future studies aimed at detailed structure function analyses 376	
may provide mechanistic insights into the functional domains of CD34 required for 377	
modulating integrin sorting and function.  378	
 379	
CD34 is a marker for progenitor subsets of non-hematopoietic cell types including 380	
muscle satellite cells, hair follicle stem cells, and mesenchymal progenitors (5-8).  It has 381	
been postulated that its utility as an enrichment marker for undifferentiated cells could be 382	
extended to epithelial progenitors of the lung, namely bronchoalveolar stem cells 383	
(BASCs).  These cells are proposed to exist at BADJs and have the potential to give rise 384	
to terminal epithelial cells of the bronchioles and distal airways (9).  However, 385	
subsequent studies have reported that epithelial lineages lack CD34 expression (31, 56, 386	
57).  In the current manuscript we have used Cd34-/- mice, immunofluorescence staining 387	
of tissue sections, and spatial localization in lung to address this issue.  By confocal 388	
analyses of naïve lung, we do not observe co-expression of CD34 and epithelial markers 389	
in BADJs.  This is corroborated by the absence of CD34 expression by any EpCam+ 390	
epithelial fraction of lung-derived cells, a subpopulation believed to contain epithelial 391	
progenitor cells (56).  Instead, CD34 is expressed by vascular endothelia and 392	
mesenchymal cells including vimentin+ fibroblasts and PDGFRα+ Sca1+ FAPs.  FAPs 393	
were previously characterized as stromal cells that support skeletal muscle regeneration, 394	
and were more recently described in the lung as lipofibroblasts of the alveolar niche with 395	
an analogous function (32, 58).  Previously we found that CD34 is dispensable for normal 396	
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function of FAPs (59).  This is consistent with our observations that lung FAPs, in an 397	
acute response to BLM, expand in similar numbers and display similar rates of 398	
proliferation in WT and Cd34-/- animals.  However, we may not formally rule out an 399	
additional role for CD34 in lung FAPs; the intimate association of these cells with the 400	
endothelium and their known role in tissue repair and matrix production highlights the 401	
importance of endothelial-FAP cell cross talk. 402	
 403	
In summary, our data suggest that vascular CD34 serves a protective function during lung 404	
injury by enhancing the endothelial/matrix interactions and thereby preventing 405	
delamination and reducing permeability.  Future structural and functional studies 406	
designed to identify the requisite domains of the molecule could offer insights into how 407	
this function could be modulated to treat pulmonary edema. 408	
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Figure legends 618	
 619	
Figure 1. BLM-treated Cd34-/- mice have increased incidence of mortality and 620	
weight loss but comparable fibrotic responses to WT mice. Mortality rates of WT and 621	
Cd34-/- mice challenged with a single dose of (A) 5.0 U/kg or (B) 2.5 U/kg BLM (e.t.). 622	
(A) P < 0.001 (n=3 or 5 per group).  Data are from a single experiment. (B) P < 0.02 623	
(n=8 or 9 per group).  One of two independent experiments.  Significance determined by 624	
log-rank test. (C) Weight loss of WT and Cd34-/- mice following treatment of 1.6 625	
U/mouse BLM (i.v.). *, P < 0.05, Student’s t-test (n=7-9 per group).  Plots shown are 626	
representative of two independent experiments.  (D) Representative Masson’s trichrome-627	
stained lung sections of WT and Cd34-/- mice 21 days after BLM treatment (2.5 U/kg). 628	
Scale bar = 200 µm.  (E) Percent fibrotic area determined by quantifying area of fibrotic 629	
lesions normalized to total tissue area. ns, P > 0.05, Mann-Whitney test (n=10 or 5 per 630	
group) (F) Static elastance (Est) measurements of PBS and BLM-treated WT and Cd34-/- 631	
mice. *, P < 0.05, Mann-Whitney test (n=3-4 per PBS-treated group; n=4-5 per BLM-632	
treated group). 633	
 634	
Figure 2. BLM-induced acute lung inflammatory response is comparable in Cd34-/- 635	
and WT mice. (A) Enumeration of total CD45+ hematopoietic cells in the BALF of mice 636	
treated with PBS (naïve) or BLM; mice were sacrificed and tissues harvested Day 3 or 6 637	
post-treatment as indicated.  (B) Differential analysis of infiltrating leukocyte subsets in 638	
the BALF by flow cytometry using the surface markers CD11c+ (myeloid cells), Ly6B+ 639	
(7/4) (neutrophils), CD11c- SiglecF+ (eosinophils), CD3e+ (T lymphocytes), and B220+ 640	
(B lymphocytes).  *, P < 0.05, Mann-Whitney test (n=3 per PBS-treated group; n=4-8 per 641	
BLM-treated group).  Representative data from two independent experiments. (C) 642	
Quantification of IL-1β, IL-6, CXCL1, TNFα in BAL fluid and lung homogenates of 643	
naive mice or BLM-treated mice six days after injury (n=3-4 per PBS treated group; n=6-644	
7 per BLM-treated group).  Representative data from two independent experiments. 645	
 646	
Figure 3. CD34-deficiency results in increased pulmonary vascular leak following 647	
BLM-induced injury. (A) Vascular permeability was assessed by a modified Mile’s 648	
	 22 
assay six days after endotracheal BLM instillation.  Data presented as µg EBD extracted 649	
per gram of lung tissue.  *, P = 0.014, Student’s t test (n=7 per group).  (B) Pearson 650	
correlation of vascular leak and percent of initial body weight of Cd34-/- mice. P = 0.19, 651	
r2 = 0.315.  Representative data from two independent experiments. 652	
 653	
Figure 4. Lung tissue ultrastructure reveals interstitial edema in BLM-challenged 654	
Cd34-/- mice. Transmission electron micrographs of (A-C) WT and (D-F) Cd34-/- lung 6 655	
days after BLM-induced lung injury.  Images shown are representative of at least 50 656	
fields of view per sample.  Lung specimens were sampled from four mice per genotype.  657	
AL, alveolus; EN, endothelial cell; F, fibroblast; T1, type 1 alevolar epithelial cell 658	
(AEC); T2, type 2 AEC; CL, capillary lumen; RBC, erythrocyte; COL, collagen; EL, 659	
elastin; INT, interstitium; E, edema. 660	
 661	
Figure 5. CD34 is expressed by vascular endothelia and mesenchymal subsets but 662	
not epithelial cells in naïve mouse lung. (A-C) Confocal images from z stacks 663	
demonstrating CD34 co-expression with podocalyxin (Podxl) + endothelial cells and (A) 664	
PDGFRα + and (B) vimentin+ fibroblasts. (C) E-cadherin (E-cad) + and surfactant protein 665	
C (Sfpc)+ epithelial cells do not express CD34; inset displays higher magnification of a 666	
bronchoalveolar duct junction (BADJ). Scale bars = 50 µm and inset scale bar = 10 µm. 667	
Bv, blood vessel; br, bronchiole.  (D) Histograms represent relative fluorescence intensity 668	
of a CD34 specific antibody to cellular subsets gated for CD31+ endothelia, PDGFRα+ 669	
Sca1+ fibroadipogenic progenitors (FAPs), or EpCam+ epithelial cells.  Representative 670	
results from 2-3 naive animals.  (E) Flow cytometric analysis of FAP percentages in the 671	
lineage negative (CD45-, CD31-) fraction of naïve mice (PBS) and in mice six days after 672	
BLM treatment (e.t.) (BLM). (F) Quantification of EdU uptake indicates lung FAP 673	
proliferation in response to BLM-induced injury. n.s., P > 0.05, Mann-Whitney test (n=2, 674	
3 per PBS-treated group; n=5-6 per BLM-treated group). 675	
 676	
Figure 6. Loss of CD34 in non-hematopoietic tissues results in increased sensitivity 677	
to BLM challenge. (A) BMT mice were generated by transplanting CD45.1 bone 678	
marrow cells into lethally irradiated WT or Cd34-/- host animals. (B) Survival curves of 679	
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mice treated with 2.5 U/kg BLM (e.t.).  P < 0.02, log rank test  (n=6-9 per group).  (C) 680	
Weight loss of mice challenged with 1.6 U/mouse BLM (i.v.).   *, P < 0.05, Mann-681	
Whitney test (n=5-7 per group).  (D) Lethally irradiated CD45.1 mice were reconstituted 682	
with bone marrow cells from WT or Cd34-/- mice.  (E) Survival curves of mice treated 683	
with 2.5 U/kg BLM (e.t.) (n=5-6 per group).  (F) Weight of BM chimeras challenged 684	
with 1.6 U/mouse BLM (i.v.) (n=6 per group). 685	
 686	
Figure 7. Cd34-/- mice display increased weight loss and more pronounced tissue 687	
remodeling after influenza infection. (A) Weight loss of WT and Cd34-/- mice 688	
following intranasal infection with influenza A/PR8. *P > 0.05; * P > 0.01; ***P > 0.001, 689	
Student’s t test (n=8 per group).  (B-C) Enumeration of total CD45+ hematopoietic cells 690	
and leukocyte subsets in the BALF of influenza infected mice (n = 4 or 6 mice per group).  691	
(D) Quantification of damaged area normalized to total tissue area 12 days after influenza 692	
infection. *, P > 0.05, Student’s t test (n=8 or 10 per group).  (E) Representative 693	
hematoxylin and eosin stained lung sections of WT and Cd34-/- mice 12 days after 694	
infection.  (F) Immunofluorescent images of lung sections as shown in (E) stained for 695	
podocalyxin (Podxl, red) and keratin 5 (Krt5, blue). Scale bar = 200 µm. Bv, blood 696	
vessel; br, bronchiole.  Representative data from two independent experiments. 697	
 698	
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